May 01 2021 Read 4 Times
University of Sheffield spinout company, Rinri Therapeutics, has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund, to support the development of its novel stem cell therapy to treat sensorineural hearing loss (SNHL).
The company’s underlying technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield. It seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear.
SNHL happens when there is damage to the hair cells in the cochlea and/or to the auditory nerve. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.
Rinri Therapeutics, a Sheffield, England, UK-based biotechnology company developing a novel stem cell therapy to restore hearing, raised a total of £10m in funding.
Backers included existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund.
The proceeds will support the development of the company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Led by Dr Simon Chandler, CEO, Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company’s technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. There are currently no pharmacological treatment options for SNHL patients.
Search jobs Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund
Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Rinri’s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. There are currently no pharmacological treatments available for SNHL despite t
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
News provided by
Share this article
Share this article
SHEFFIELD, England, April 20, 2021 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company s novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Rinri s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hai
Rinri Therapeutics Appoints Experienced Life Science Executive Nick Higgins as Chairman
Extensive private and public company corporate development track record
Significant expertise in cell and gene therapy
News provided by
Share this article
Share this article
SHEFFIELD, England, Feb. 1, 2021 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announces the appointment of Nick Higgins as Chairman of the Board. He takes over from Dr Erica Whittaker who has served as Chair since the creation of Rinri Therapeutics.
Nick s career spans over 35 years in the life science industry during which he gained extensive knowledge of UK and US markets in both private and public sectors. Nick was the former Chief Executive Officer (CEO) of Intercytex Group plc, a company focused on the development and manufacturing of cell therapy products which was subsequently sold through a series of asset sales. He also served as Chi